Results 331 to 340 of about 2,594,817 (409)

Drug Use After Emergency Department‐Initiated Injectable Buprenorphine: A Secondary Analysis of the ED‐INNOVATION Ancillary Safety and Feasibility Trial

Academic Emergency Medicine, EarlyView.
ABSTRACT Study Objective To characterize opioid and nonopioid drug use in the week following emergency department (ED)‐initiated extended‐release buprenorphine (XR‐BUP) treatment using both self‐reported data and urine drug screens (UDS). Methods This study uses data collected during a nonrandomized clinical trial of patients with untreated opioid use ...
Ethan Cowan, Gail D'Onofrio, Jeanmarie Perrone, Erik Anderson, James Dziura, Kathryn Hawk, Andrew Herring, Ryan McCormack, Manali Phadke, Elizabeth A. Samuels, David A. Fiellin   +10 more
wiley   +1 more source

Developing predictive models for µ opioid receptor binding using machine learning and deep learning techniques. [PDF]

Exp Biol Med (Maywood)
Liu J, Li J, Li Z, Dong F, Guo W, Ge W, Patterson TA, Hong H.   +7 more
europepmc   +1 more source

High‐ and low‐dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: A randomized control trial

Alcohol, Clinical and Experimental Research, EarlyView.
Participants (n = 236) from three sites were randomly assigned to either placebo, low‐dose topiramate (up to 125 mg/day), or high‐dose topiramate (up to 250 mg/day) for up to 18 weeks. Exploratory analyses indicated that participants treated with the high dose had lower mean percentage of heavy drinking days and drinks per day than those taking the low
Jason D. Robinson, Robert M. Anthenelli, Paul M. Cinciripini, Maher Karam‐Hage, Yong Cui, George Kypriotakis, Nassima Ait‐Daoud Tiouririne   +6 more
wiley   +1 more source

A new pathway for neuroprotection against tau hyperphosphorylation via δ-opioid receptor initiated inhibition of CDK5 and AMPK signaling. [PDF]

Front Aging Neurosci
Li J, Xu Y, Balboni G, Xia Y.
europepmc   +1 more source

Effects of cannabidiol in alcohol use disorder patients with and without co‐occurring post‐traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof‐of‐concept trials

Alcohol, Clinical and Experimental Research, EarlyView.
Two small placebo‐controlled trials evaluated the effects of cannabidiol (CBD) in patients with alcohol use disorder (AUD), with and without co‐occurring post‐traumatic stress disorder (PTSD). CBD was rapidly absorbed and generally well tolerated in dosages of up to 1200 mg/day. Both treatment groups showed large reductions in drinking.
Michael P. Bogenschutz, Esther Blessing, Danielle Dgheim, Dayeon Cho, Jun Zhang, Eugene M. Laska, Charles R. Marmar   +6 more
wiley   +1 more source

Peripheral opioid receptor antagonism alleviates fentanyl-induced cardiorespiratory depression and is devoid of aversive behavior. [PDF]

Elife
Ruyle BC, Masud S, Kesaraju R, Tahirkheli M, Modh J, Roth CG, Angulo-Lopera S, Lintz T, Higginbotham JA, Massaly N, Morón JA.   +10 more
europepmc   +1 more source

Molecular mechanisms of inverse agonism via κ-opioid receptor-G protein complexes. [PDF]

Nat Chem Biol
Tyson AS, Khan S, Motiwala Z, Han GW, Zhang Z, Ranjbar M, Styrpejko D, Ramos-Gonzalez N, Woo S, Villers K, Landaker D, Kenakin T, Shenvi R, Majumdar S, Gati C.   +14 more
europepmc   +1 more source

Dark seasons enhance brain and brown adipose tissue interactions related to mu-opioid receptor signaling. [PDF]

Eur J Nucl Med Mol Imaging
Sun L, Landau AM, Tang J, Roivainen A.
europepmc   +1 more source

The efficacy and safety of kappa opioid receptor (KOR) agonists in patients with uraemic pruritus: a systematic review and network meta-analysis. [PDF]

Clin Kidney J
Yang H, Pei M, Zhai J, Zhou Z, Xing Y, Lan Q, Zhu Y, Wang X, Yang B.   +8 more
europepmc   +1 more source

Mu-opioid receptor expression on B cells as a potential biomarker for chronic pain: a follow-up study with patients with fibromyalgia. [PDF]

Pain Rep
Malafoglia V, Raffaeli W, Ilari S, Gioia C, Iannuccelli C, Tenti M, Vitiello L, Proietti S, Lupacchini L, Passacatini LC, Tomino C, Vincenzo M, Fini M, Di Franco M, Muscoli C.   +14 more
europepmc   +1 more source